iRadimed reports preliminary Q4 revenue $14.9M (+25% YoY); issues FY2023 guidance $61M-$63M

IRADIMED CORP

2022-FY EPS reported $1.02 revenue$53,303,145

Q4 2022 preliminary revenue $14.9M, up 25% YoY, above guidance of $14.1M-$14.8M.
Sixth consecutive quarterly revenue record; orders exceeded shipments, increasing backlog.
FY2023 guidance: revenue $61M-$63M, GAAP EPS $1.10-$1.20, non-GAAP EPS $1.23-$1.34.
Q1 2023 guidance: revenue $14.6M-$14.9M, GAAP EPS $0.23-$0.25, non-GAAP EPS $0.26-$0.28.
Full year 2022 revenue grew 27.5% over 2021.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IRADIMED CORP reported the full year 2023 results: revenue $61 million to $63 million, EPS GAAP diluted earnings per share of $1.10 to $1.20, and non-GAAP diluted earnings per share of $1.23 to $1.34. Guidance initiated.

Period: the full year 2023
Revenue: $61 million to $63 million
EPS: GAAP diluted earnings per share of $1.10 to $1.20, and non-GAAP diluted earnings per share of $1.23 to $1.34
Guidance: initiated
Result: guidance update

Exact text from the filing

For the full year 2023, the Company expects to report revenue of $61 million to $63 million, GAAP diluted earnings per share of $1.10 to $1.20, and non-GAAP diluted earnings per share of $1.23 to $1.34.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IRADIMED CORP reported the fourth quarter ended December 31, 2022 results: revenue $14.9 million.

Period: the fourth quarter ended December 31, 2022
Revenue: $14.9 million
Result: preliminary results

Exact text from the filing

Fourth-quarter revenue is expected to be approximately $14.9 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IRADIMED CORP reported the first quarter of 2023 results: revenue $14.6 million to $14.9 million, EPS GAAP diluted earnings per share of $0.23 to $0.25, and non-GAAP diluted earnings per share of $0.26 to $0.28. Guidance initiated.

Period: the first quarter of 2023
Revenue: $14.6 million to $14.9 million
EPS: GAAP diluted earnings per share of $0.23 to $0.25, and non-GAAP diluted earnings per share of $0.26 to $0.28
Guidance: initiated
Result: guidance update

Exact text from the filing

For the first quarter of 2023, the Company expects to report revenue of $14.6 million to $14.9 million, GAAP diluted earnings per share of $0.23 to $0.25, and non-GAAP diluted earnings per share of $0.26 to $0.28.

View on SEC.gov

Browse all earnings releases →

IRADIMED CORP filing history →

Source: SEC EDGAR

accession 0000898432-23-000021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.